Thermo Fisher Scientific Palivizumab Monoclonal Antibody (7B3)

Applications

• ELISA (ELISA)
  Tested Dilution: 0.001–0.1 µg/mL

Product Specifications

Product Specific Information

• Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
• Competitive ELISA recommended dilution: 5–30 µg/mL
• The lyophilized product remains stable up to 1 year at -20°C from date of receipt.
• Upon reconstitution, store for 2–3 weeks at 2–8°C or up to 12 months at -20°C or below.
• Avoid repeated freeze/thaw cycles.

Target Information

Palivizumab (trade name: Synagis) is an FDA-approved drug for the prevention of respiratory syncytial virus (RSV) infections. It is a recombinant humanized IgG1 kappa monoclonal antibody that binds to the RSV envelope fusion protein (RSV F) on the virus surface, blocking a critical step in the membrane fusion process.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.